Half Year Results announcement for 2013/14

Half Year Results announcement for 2013/14

Melbourne, Australia — 12/02/2014

US Settlement Impacts Half Year Profit
Exceptional Performance in Specialty Products
Full Year Profit Guidance Re-Affirmed

CSL Limited (ASX:CSL) today announced a net profit after tax (NPAT) of US$646 million for the six months ended 31 December 2013, up US$21 million or 3% on a reported basis when compared to the prior comparable period (PCP). The result included a one-off U.S. antitrust class action litigation settlement of US$64 million, or US$39 million after tax.

  • Revenue US$2,691 million, up 5% on PCP
    - Up 6% at constant currency1
  • EBIT US$818 million, up 5%
    - Up 2% at constant currency 
  • NPAT US$646 million, up 3% on PCP
    - Up 2% at constant currency
  • Research and development investment increased to US$229 million
  • Interim dividend2 increased to US$0.53 per share, unfranked for Australian tax purposes, payable on 4 April 2014
    - Converted to Australian currency, interim dividend increased to approximately A$0.59 per share, up 21% on PCP


  • Hizentra® (subcutaneous immunoglobulin)
    - U.S. approval for bi-weekly administration
    - Japanese approval for treatment of primary immune deficiency and secondary immune deficiency
  • Kcentra® (4 factor pro-thrombin complex concentrate) - approved by U.S. FDA for surgical use
  • CSL 362 (acute myeloid leukaemia) – license agreement with Janssen Biotech, Inc.
  • CSL 112 (acute coronary syndrome) – global phase IIb clinical trial commencing in 2014
  • Alpha-1 (hereditary lung / liver disease) – innovative diagnostic test kit launched
  • A$950 million share buyback3 22% complete
  • Agreement to settle U.S. antitrust class action litigation
  • Establishing a sponsored Level 1 American Depository Receipts program

Download this release: 
PDF icon CSL Half Year Results Announcement for 2013/14 (0.30Mb)

Additional resources:
The Webcast, Analyst presentation and Full Year information is also available. More ...

For further information, please contact:

  Mark Dehring
  Head of Investor Relations
  CSL Limited
  Phone: +613 9389 2818
  Email: mark.dehring@csl.com.au
  Sharon McHale
  Senior Director Public Affairs
  CSL Limited
  Phone: +613 9389 1506
  Mobile: +614 0997 8314
  Email: sharon.mchale@csl.com.au
  Tim Duncan
  Hintons & Associates
  Phone: +613 9600 1979
  Mobile: +614 0844 1122
  Email:   tduncan@hintons.com.au

1 Constant currency removes the impact of exchange rate movements to facilitate comparability. See end note (#) in the PDF for further detail.
2 For shareholders with an Australian registered address, dividends will be paid in A$ at an amount of A$0.588830 per share (at an exchange rate of A$1.1110/US$1.00), and for shareholders with a New Zealand registered address, dividends will be paid in NZD at an amount of NZ$0.639021 per share (at an exchange rate of NZ$1.2057/US$1.00). The exchange rates used are fixed at the date of dividend determination. All other shareholders will be paid in US$.
3 CSL reserves the right to suspend or terminate buy-backs at any time.

© 2017 CSL Limited